Cargando…

Is haploinsufficiency a sufficient mechanism for MYBPC3 truncating mutations?

Reduced expression of MYBPC3 causes early dysfunction in human cell culture models prior to reduced cMyBP-C levels.

Detalles Bibliográficos
Autor principal:	Barefield, David Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072154/ https://www.ncbi.nlm.nih.gov/pubmed/36946992 http://dx.doi.org/10.1085/jgp.202313351

Ejemplares similares

Oxidative Stress in Dilated Cardiomyopathy Caused by MYBPC3 Mutation
por: Lynch, Thomas L., et al.
Publicado: (2015)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy
por: Suay-Corredera, Carmen, et al.
Publicado: (2021)

Fatal neonatal hypertrophic cardiomyopathy caused by compound heterozygous truncating MYBPC3 mutation
por: Alsters, S., et al.
Publicado: (2019)

High-Throughput Diagnostic Assay for a Highly Prevalent Cardiomyopathy-Associated MYBPC3 Variant
por: Barefield, David Y, et al.
Publicado: (2016)

Is MYBPC3 linked to bicuspid aortic valve?
por: Niaz, Talha, et al.
Publicado: (2021)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain
por: Fernández Suárez, Natalia, et al.
Publicado: (2023)

Novel MYBPC3 Mutations in Indian Population with Cardiomyopathies
por: Rani, Deepa Selvi, et al.
Publicado: (2023)

An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
por: Tudurachi, Bogdan-Sorin, et al.
Publicado: (2023)

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status
por: Jansen, M., et al.
Publicado: (2021)

An interesting Mybpc3 heterozygous mutation associated with bicuspid aortic valve
por: Zhao, Xiaopei, et al.
Publicado: (2020)

Familial hypertrophic cardiomyopathy associated with a new mutation in gene MYBPC3
por: Aurensanz Clemente, Esther, et al.
Publicado: (2017)

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
por: Ehlermann, Philipp, et al.
Publicado: (2008)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Autosomal Recessive Transmission of MYBPC3 Mutation Results in Malignant Phenotype of Hypertrophic Cardiomyopathy
por: Wang, Yilu, et al.
Publicado: (2013)

The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy
por: Jørgenrud, Benedicte, et al.
Publicado: (2015)

Haploinsufficiency for Tumor Suppression: The Hazards of Being Single and Living a Long Time
por: Largaespada, David A.
Publicado: (2001)

MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
por: McNamara, James W., et al.
Publicado: (2017)

A novel truncating variant of SPAST associated with hereditary spastic paraplegia indicates a haploinsufficiency pathogenic mechanism
por: Nan, Haitian, et al.
Publicado: (2022)

A Novel Loss-of-function Mutation in MYBPC3 Causes Familial Hypertrophic Cardiomyopathy with Extreme Intrafamilial Phenotypic Heterogeneity
por: Peng, Y, et al.
Publicado: (2023)

CRISPR-mediated gene editing to rescue haploinsufficient obesity syndrome
por: Wang, Zhifeng, et al.
Publicado: (2019)

Haploinsufficiency of KMT2D is sufficient to cause Kabuki syndrome and is compatible with life
por: Luperchio, Teresa Romeo, et al.
Publicado: (2019)

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022)

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy
por: Ni, Erru, et al.
Publicado: (2023)

Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload
por: Ma, Zhen, et al.
Publicado: (2018)

Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy
por: Caiazza, Martina, et al.
Publicado: (2020)

Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity
por: Vinodhini, M. Thirumalai, et al.
Publicado: (2018)

Phenotypic Diversity of Cardiomyopathy Caused by an MYBPC3 Frameshift Mutation in a Korean Family: A Case Report
por: Park, Joonhong, et al.
Publicado: (2021)

MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis
por: Zou, Xiaodong, et al.
Publicado: (2022)

Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing
por: Liu, Xuxia, et al.
Publicado: (2015)

Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function
por: Birket, Matthew J., et al.
Publicado: (2015)

Necessary but not sufficient: unique author identifiers
por: Harrison, Andrew Marc, et al.
Publicado: (2016)

Is There Sufficient Evidence for Criticality in Cortical Systems?
por: Destexhe, Alain, et al.
Publicado: (2021)

NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
por: Zhang, Yueqi, et al.
Publicado: (2023)

MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations
por: Lin, Li-rong, et al.
Publicado: (2022)

Increased myofilament Ca(2+) sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice
por: Fraysse, Bodvaël, et al.
Publicado: (2012)

Myocardial fibrosis comparison by cmr between genetically positive HCM patients with MYBPC3 and MYH7 gene mutations
por: Villanueva, Alejandra, et al.
Publicado: (2015)

MYBPC1 is a key regulator for laryngeal carcinoma formation
por: Liu, Jing, et al.
Publicado: (2022)

Platelet Activation and Clopidogrel Effects on ADP‐Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3
por: Li, R.H.L., et al.
Publicado: (2016)

Vitamin D and anesthesia: Is our present knowledge sufficient?
por: Goudra, Basavana G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uiilfju1fh1h0rpk8ug5rgpkum